First and only approved anti-CD38 therapy in combination with 3 medications (VRd) for patients newly diagnosed multiple myeloma (NDMM) not eligible for autologous stem cell transplant (ASCT) Sarclisa® reduces the… Read More
VANCOUVER, BC – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate its Scientific Advisor… Read More
Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced… Read More
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer,… Read More
